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ABSTRACT 
Introduction. In chronic hepatitis B (CHB) patients, fibrosis assessment during antiviral treatment 
is a key step in the clinical management. Objective. To evaluate the performance of elastography in 
assessing fibrosis stage in CHB before and after two years of nucleoside/nucleotide analogues 
(NUC) treatment in comparison with indirect serum markers. Methods. CHB diagnosis was made 
according to standard criteria. A clinical and virological evaluation was performed at baseline and 
again at 3, 6, 9, 12 18, and 24 months during treatment. Fibrosis was evaluated by liver biopsy, 
elastography and indirect serum markers. Results. Of 75 patients, 50 had CHB, HBeAg negative 
and were deemed eligible for this study. Of these, 22 underwent liver biopsy. Mean histo-
morphometric values of fibrotic tissue differed significantly in the stage < S3 vs. stage ≥S3: 
2.01± 2.62%vs. 12.85± 7.31% (p=0.03), respectively. At 18 and 24 months, stiffness values were 
statistically reduced from those previously observed (P=0.03 and P<0.001). At 24 months the 
values of APRI, FIB-4 and LOK were not different from baseline values, while the FORNS score at 
24 months was the only one statistically. In two patients with fibrosis stage S3 and S6, respectively, 
fibrosis regressed to stage S2 and S5. In conclusion, the results of the present study show that liver 
histology, stiffness and FORNS score improve significantly during a long-term follow-up of HBV 
patients successfully treated with NUC. These results strongly suggest that the non-invasive 
evaluation of liver fibrosis represents a key step in the management and treatment of chronic HBV 
hepatitis.  
Keywords: fibrosis, liver stiffness, HBV, nucleos(t)ide analogues, entecavir, tenofovir 
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INTRODUCTION 
Chronic liver disease represents a major public health problem worldwide due to its morbidity, 
mortality, and associated economic costs (Minino et al., 2007). The introduction of an effective 
vaccine against the hepatitis B virus (HBV) has reduced the prevalence of hepatitis, as well as its 
health and economic impact in industrialised countries. In Europe, the WHO estimates that 13.3 
million people are HBV infected and Italy falls among the countries with low endemicity (positivity 
for HBsAg < 2%) (Schweitzer et al., 2015; Stasi et al., 2015).  
According to the latest international recommendations, antiviral treatment for CHB needs to be 
considered in the presence of HBV-DNA>2,000 IU/mL, elevated ALT, and/or moderate liver 
fibrosis (Ishak ≥ 2). In HBeAg positive patients, the primary therapeutic goal is to achieve a stable 
seroconversion HBeAg/anti-HBe. Patients with immune tolerance or high levels of viremia (HBV 
DNA>2x107 IU/mL) do not require treatment in the absence of hepatocellular damage, although 
they should still be monitored. Tenofovir, entecavir and peginterferon alfa-2a are the preferred first-
line treatments for both HBeAg-positive and HBeAg-negative CHB infected patients (Carosi et al., 
2011). 
Some studies suggest that the complete long-term suppression of HBV replication by 
nucleosides/nucleotides results in a long-term improved outcome that significantly reduces the risk 
of developing liver cirrhosis, hepatocellular insufficiency, and, hepatocellular carcinoma (CDC, 
2013). Moreover, longitudinal histopathological evaluation has demonstrated a regression of liver 
tissue fibrosis during entecavir/tenofovir therapy (Papachrysos et al., 2015).  
To date, few studies have evaluated the longitudinal changes of liver fibrosis in CHB positive 
patients with transient elastography (TE). The aim of the current study was therefore to evaluate 
whether TE and indirect serum markers could represent a valuable clinical resource for monitoring 
tissue fibrosis during and after antiviral therapy.   
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MATERIALS AND METHODS 
Patients with HBV referred between January 2010 and December 2015 to the Hepatology outpatient 
services of the Azienda Ospedaliero Universitaria Careggi (AOUC), Florence, Italy, were 
considered for the study. 
The treatment of HBV patients was established in accordance with the Stresa guidelines (Carosi et 
al., 2007). 
The study was clearly explained to the patients, and their written informed consent was obtained. 
An information form on the study design and on the treatment of clinical data collected during the 
same protocol was released to each patient. There was no restriction regarding current treatments 
for other diseases except for those therapies/diseases listed in the exclusion criteria. 
Inclusion criteria were as follows: patients naïve to antiviral treatment with nucleoside/nucleotide 
analogues, aged between 18 and 70 years, HBsAg positive, HBV DNA> 2000 IU/mL, HBeAg 
negative, anti-HBe positive, with liver fibrosis assessed by liver biopsy or by FibroScan; patients 
naïve to treatment presenting clinical and biochemical diagnosis of HBV related cirrhosis (biopsy 
was not performed for these patients). Exclusion criteria were as follows: ALT > 5 x ULN, HBeAg 
positive patients, BMI>30, coinfections (HIV, HCV, HDV), pregnancy, connective tissue diseases, 
psychiatric illnesses compromising compliance with therapy, presence of ascites at ultrasound, 
hepatocellular carcinoma (HCC), alcohol or drug related liver disease, treatment with 
corticosteroids and/or interferon alpha in the six months prior to enrolment in the study, resistance 
to antiviral treatment or the presence of side effects requiring an association or replacement with 
another drug. 
NON-INVASIVE ASSESSMENT 
Indirect serum markers 
All patients were assessed with the following surrogate markers of liver fibrosis: APRI (Wai et al., 
2003), FIB-4 (Vallet-Pichard et al., 2007), Forns score (Forns et al., 2002), Lok score (Lok et al., 
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2005). The above scores were calculated using biochemical tests carried out within one month 
before liver biopsy. The same tests were repeated and the scores calculated 24 months following the 
initiation of treatment. 
The entire cohort of patients evaluated by Ishak score, together with the cirrhotic patients on 
the basis of clinical and ultrasound evaluation, was evaluated with HUI score (HUI et al., 
2005), a non-invasive biomarker validated for HBV to distinguish between significant and non 
significant fibrosis.   
Transient elastography  
Liver stiffness was measured using FibroScan® (Echosens, Paris, France), according to the 
manufacturer instructions. In all patients, TE was performed after an overnight fasting (Arena et al., 
2013). The median values of ten successful acquisitions, expressed in kilopascal (kPa), were 
considered representative of liver stiffness. Procedures with 10 successful acquisitions, with a 
success rate of at least 60% and an interquartile range (IQR) lower than 30% of the median value, 
were considered reliable. Liver stiffness was measured at commencement, and again at at 3, 6, 9, 12 
18, and 24 months during treatment. 
INVASIVE ASSESSMENT 
Liver biopsy 
On the same study day, patients underwent a measurement of liver stiffness by TE. Ultrasound-
guided percutaneus liver biopsy was then performed on the right lobe of the liver with a 16-gauge 
semiautomatic modified Menghini needle system (BIOMOL; Hospital Service, Aprilia, Italy) under 
local anaesthesia. Liver specimens were formalin-fixed and paraffin-embedded for histological 
evaluation. Sections of liver tissue were stained with haematoxylin, eosin and Sirius red. These 
were then examined by an experienced pathologist who was unaware of the liver stiffness results. 
All liver specimens had a length >25 mm and included at least 11 complete portal tracts, reflecting 
adequate standards (Guido et al., 2004). The presence of necro-inflammatory activity (grading) and 
fibrosis (staging) was established according to the method proposed by Ishak (Ishak et al., 1995). 
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Each unit participating in the study, if external to AOUC, has provided three paraffin sections in 
black. At the end of the study, histopathological examination of all samples (pre- and post-
treatment) was repeated by a pathologist. In the event of disagreement between the two pathologists, 
a review of the scoring by collegial observation was scheduled. 
Morphometry 
Only the sections of each biopsy stained with Sirius red were used for calculating the 
percentage of collagen, which was performed by one author (C.S.). The percentage of collagen 
content was calculated by digital image analysis (Documentation – RSB Home Page). This 
software enables, through a grey scale slider, to select the total tissue area of liver biopsy. 
Subsequently, red, green, and blue (RGB) light channels were used to select the collagen area. 
Before the measurement of liver fibrosis structural collagen in large portal tracts, blood vessel 
walls, artefacts, vascular cavities, and lymphoid aggregates were eliminated. The results of the 
digital analysis were compared with the standard Ishak score (Ishak et al., 1995).  
 
Statistical analysis 
All results are expressed as mean ±standard deviation. After checking similar variances within the 
groups using Levine’s test for equality of variances, the numerical comparison of continuous data 
was performed using the Student’s t-test for unpaired and for paired samples with Bonferroni 
correction. Statistical significance was set at p < 0.05. 
To evaluate factors associated with hepatic fibrosis, patients were divided in 2 groups: 
patients with non significant (< 6 kPa) or significant fibrosis (≥ 6 kPa) along the EASL-ALEH 
guidelines (2015). Univariate analysis explored each variable in a data set, including red blood 
cells, white blood cells, platelets, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), alpha-fetoprotein, gamma-glutamyltransferase (GGT), ferritin, sideremia, creatinine, 
glucose, cholesterol, INR, bilirubin, albumin and all non invasive serum markers. 
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Logistic regression models were used for multivariate analysis to identify the most significant 
correlation among the variables. All variables in univariate analyses with P<0.05 were 
introduced into the multivariate analysis. 
 
RESULTS 
The study evaluated 75 patients (48 males and 27 females, mean age 48.45 ± 13.98). Of these, 50 
CHB, HBeAg negative patients were deemed eligible. The mean stiffness value of these patients 
was 10.52 ± 6.05 kPa. The biochemical parameters of the entire study population are shown in 
Table 1. Baseline values of APRI, FORNS, FIB-4 and LOK were 0.91± 1.65, 4.5± 1.93, 0.73± 0.68, 
0.29± 0.17, respectively. In these patients, when univariate analysis was conducted to evaluate 
factors associated with liver fibrosis, the parameters associated with significant fibrosis 
(stiffness >6 kPa) were ALT, AST,GGT, APRI, FORNS, LOK (Table 2). However, after the 
multivariate analysis these parameters had no relationship with hepatic fibrosis. No 
relationship with liver fibrosis was found for non significant fibrosis. Twenty-two patients 
agreed to undergo a pre-treatment liver biopsy. Out of twenty-two patients, 17 patients had Ishak 
score ≥S2 (3 patients with histological evaluation of liver cirrhosis). Taking into account the 
cohort of patients who underwent liver biopsy together with cirrhotic patients  based on 
clinical and ultrasound evaluation we found that the percentage of patients with HUI > 0.15 
(corresponding to Ishak score>S3) was 45%(N=10). The mean value for HUI score ≤0.15 was 
0.033±0.017 and the mean value for HUI score was 0.39±0.31.  
All section of liver biopsies, stained with Sirius Red were analized with image analysis. The 
mean histo-morphometric values of fibrotic tissue was 6.83±7.03. 
Patients were divided into 2 groups according to Ishak score: 12 patients were in histological 
stage <S3, 10 were in histological stage ≥S3. Mean histo-morphometric values of fibrotic tissue 
differed significantly in the stage < S3 vs. stage ≥S3II: 2.01± 2.62%vs. 12.85± 7.31% (p=0.03), 
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respectively (Fig.1 ). A statistically significant correlation was found between morphometry 
and elastography (p < 0.001), morphometry and LOK (p = 0.05), and morphometry and APRI 
(p = 0.022). 
Twenty-two patients were eligible for treatment (entecavir or tenofovir) and agreed to continue the 
follow-up.  
 
Longitudinal evaluation 
To avoid the potential bias related to patients lost to follow-up, the difference between the mean 
values of basal stiffness and those of the follow-up was only calculated in 20 patients (one  was lost 
to follow-up during therapy and one developed hepatocellular carcinoma) of the 50 who initially 
enrolled. Four patients had cirrhosis, on the basis of clinical and ultrasound evaluation, and 3 
patients, on the basis of histological evaluation. All patients experienced response to treatment. 
The difference between the mean values of the initial stiffness (12.60 kPa±6.31) of the patients with 
two years of follow-up and that of the 30 patients (6.82 kPa ±1.07) without follow-up was 
significantly different (p <0.001). Stiffness values were available for 20 patients over two years of 
treatment (Fig. 2). After three months of treatment, HBV DNA was still detectable in seven patients 
with ≥2 log reduction of viral load. Mean stiffness values (9.76 kPa±3.82) were not significantly 
different from those observed prior to therapy (12.60 kPa±6.31) (p = 0.15). After six months, HBV 
DNA was still detectable in four patients. Mean stiffness values (8.78 kPa±3.24) were not 
significantly different from those observed prior to therapy. After nine months, HBV DNA was still 
detectable in two patients. Mean stiffness values at nine months (8.46 kPa±2.94) were not 
significantly different from those observed previously. After 12 months, HBV DNA was not 
detectable in all patients (8.42 kPa±2.7). Mean stiffness values at 12 months were not statistically 
different from those observed previously. After 18 months (7.85 kPa±2.26) and 24 months (7.28 
kPa±3.17) the difference between the mean values of basal stiffness and those of the follow-up were 
statistically different (P=0.03 and P<0.001) (Fig. 2). 
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Baseline values of APRI, FIB-4 and LOK were not different from those observed at 24 months 
during therapy (0.36±0.28; 0.74 ±0.39; 0.22 ±0.08, respectively), while the FORNS score at 24 
months was statistically different from that observed during therapy (2.04 ±0.34). 
Mean ALT values during therapy were not significantly different from those observed before. No 
statistically significant correlation was found between ALT and stiffness values during treatment. 
In two patients, whose fibrosis stage was at a baseline of S3 and S6, respectively, fibrosis regressed 
to stages S2 and S5 at 24 months of therapy (Table 3).  Figure 3 shows the regression of fibrosis 
from stage S6 to S5.  
The mean values of red blood cells, white blood cells, platelets, alanine aminotransferase, 
aspartate aminotransferase, alpha-fetoprotein, gamma-glutamyltransferase, ferritin, 
sideremia, creatinine, glucose, cholesterol, INR, bilirubin, albumin during therapy were not 
significantly different from those observed before. 
 
DISCUSSION 
To our knowledge, this study is one of the few studies that quantitatively assesses liver fibrosis 
at the same time by non invasive serum markers, morphometry, Ishak score and elastography 
liver, in patients with chronic liver disease HBV-related. In our cohort the percentage of 
fibrotic tissue was 6.83±7.03 with a significant differences between  2 groups of patients with 
Ishak score <S3 or ≥S3 (2.01± 2.62%vs. 12.85± 7.31%). Moreover, we found a significant 
association between morphometry and elastography, morphometry and LOK, and 
morphometry and APRI. 
Hall et al. (2012) considered ten explanted patients for each aetiology of cirrhosis, including 
10 HBV patients they found a median value of fibrosis of 17%. Xie et al. (2011) analysed the 
collagene proportionate area by digital imaging of 53 resected liver tissue samples from HBV-
related decompensated cirrhotic patients, and they found a collagene proportionate area of 
35.93 ± 14.42% (11.24%-63.41%) in these group of patients.  
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Our data underscore the relevance of histo-morphometric evaluation in the assessment of 
chronic HBV, but they also confirm that non invasive assessment by elastography, LOK, and 
APRI can useful in patients with ALT levels <5 ULN, with the best association between 
elastography and morphometry. 
Transient elastography has been proposed for the non-invasive assessment of liver fibrosis in 
patients with chronic HCV (Stasi et al., 2009; EASL-ALEH 2015; Ferraioli et al., 2015) and 
recommended in the longitudinal evaluation of regression or progression in patients undergoing 
antiviral therapy (EASL-ALEH 2015; Ferraioli et al., 2015). Different cut-offs have been proposed 
also in HBV patients for fibrosis stage ≥ F2 and for cirrhosis (EASL-ALEH, 2015). As 
recommended by EASL-ALEH Clinical Practice Guidelines (EASL-ALEH 2015), transient 
elastography is best used to determine liver fibrosis in HBV patients with active viraemia (HBV 
DNA >2000 IU/ml) but normal ALT. Liver stiffness of 12–14 kPa often indicates liver cirrhosis in 
patients with higher transaminase levels (liver stiffness >9 in patients with normal ALT). However, 
few studies have evaluated by non invasive methodologies the fibrosis regression during treatment 
with entecavir or tenofovir, the most recent nucles(t)ide analogues.  In general in HCV patients, 
when compared to pre-treatment stiffness values, a significant reduction was observed at the end of 
treatment and at different time points thereafter for a maximum period of three years. The present 
study, although conducted in a limited number of patients, is the first in a European cohort to 
provide evidence that TE can be an effective tool to evaluate the changes in liver stiffness values 
during antiviral treatment in HBV patients. The results obtained in HBV patients are in substantial 
agreement with those reported for HCV patients undergoing treatment, and provide information on 
possible fibrosis regression following a successful antiviral treatment over a period of three years 
(Stasi et al., 2013). Accordingly, in HBV patients undergoing therapy, a significant decrease in liver 
stiffness was only observed at 18 and 24 months, likely due to fibrosis regression as confirmed by 
liver biopsy in two of such patients (Table 3). The difference in liver stiffness between baseline and 
month three can be viewed as a measure of treatment-induced reversal of inflammation; whereas the 
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drop between month three and year two may reflect regression of liver fibrosis. All the serum 
markers of fibrosis included in our evaluation, with the exception of Forns score, did not show 
statistically significant differences between baseline values and values after two years of treatment. 
Overall, our results are in agreement with the observations of Chang et al. (2010) and Papachrysos 
(2015), who have reported that histologically proven necro-inflammation and fibrosis undergo 
significant changes during effective antiviral treatment.  
Previous studies (Xu et al., 2015) in Asian cohorts have suggested that TE is a reliable technique for 
diagnosing liver fibrosis stages. Our results suggest that liver stiffness, although not exclusively 
representative of liver fibrosis, may also have value as a diagnostic discriminator for patients 
needing treatment. Along these lines, we concur with Xu et al. (2015) in concluding that liver 
stiffness measurement may be a useful alternative to liver biopsy when considering treatment.  
In addition our results provide some additional information concerning the possible antifibrotic 
outcome of the current more potent analogues, e.g. entecavir and tenofovir, when compared to 
lamivudin. Accordingly, when comparing our results with those reported by Ogawa et al (2011) in 
an Asian cohort mostly treated with lamivudin (84,4% vs. entecavir 15,6%) it appears that the 
reduction in liver stiffness observed after 2 years of treatment was significantly higher when all the 
patients were treated with entecavir/tenofovir as in our study.  
As outlined by Chatterjee et al. (2015) none of the several hundred serum markers of CLD, 
most of which for HCV, NAFLD, HCC available has been independently validated with 
optimal accuracy for early or longitudinal progression of disease (Chatterjee and Mitra). 
Although the limited number of patients our data suggest that the measurement of liver stiffness at 
baseline and during nucleoside/nucleotide analogues may be a useful methodology to assess long-
term prognosis in patients undergoing treatment for HBV-related chronic liver disease. In 
conclusion, our results strongly suggest that the evaluation of liver stiffness may significantly help 
in the correct management of CHB infection. Further studies including larger cohorts will further 
clarify the usefulness of different non-invasive methods in this clinical setting.  
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Table 1: Clinical and Laboratory Parameters in the Study Population  
 
Parameter Value Normal Range 
Age, (yrs) 48.45 ± 13.98  
BMI 25.17±3.69  
Male gender, n (%) 64%  
Red Cells (103) 4945.98 ± 534.16 F: 4.000 - 5.500  
M: 4.500 - 5.900  
White cells  5864.43 ± 1620.74 4.500 - 8.500 
Cholesterol (mg/dL) 175.47 ± 35.44 < 210  
γ-GT (U/L) 43.42 ± 61.03 10 - 40 
AST (U/L) 45.63 ± 80.62  5 - 40 
ALT (U/L) 64.76 ± 143.10 5 - 40 
Sideremia (mcg/dL) 105.38  ± 44.95 M: 65 -176  
F: 50 -170  
Platelet count (109/L) 199.26 ± 61.60  140- 440 
HBV DNA 22869.5 ± 47449.21 < 20  
Results are expressed as mean ± SD. 
Abbreviations: γ-GT, gamma glutamyl-transpeptidase; AST, aspartate transaminases; 
ALT, alanine transaminases; BMI, Body Mass Index 
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Table 2. Univariate Analysis for Factors Associated with Liver Fibrosis 
 
Parameters Mean ± standard 
deviation (Stiffness 
≥6 kPa) 
P value 
ALT(U/L) 64.9±149.42 0.0549 
AST (U/L) 46.2±84.47 0.0371 
γ-GT (U/L) 44.61±64.40 <0.001 
APRI 0.97±1.73 0.0446 
FORNS 4.55±2.00 0.0237 
LOK 0.3±0.17 0.0140 
Stiffness (kPa) 11.37± 6.13  
 
 
 
 
 
 
 
Table 3. Fibrosis regression. In 2 patients the biopsy was performed at baseline and after 2 years of 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ISHAK score 
(Baseline) 
Stiffness 
(baseline) 
Stiffness 
(3 mo.) 
Stiffness 
(6 mo.) 
Stiffness 
(9 mo.) 
Stiffness 
(12 mo.) 
Stiffness 
(18 mo.) 
Stiffness 
(24 mo.) 
ISHAK score 
 (24 mo.) 
Case 1 
(A:3,B:0,C:3,D:2) 
S:3 8,80 8,30 8,40 7,30 7,9 7,2 7 
(A2, B0, C1, D2); 
S:2 
Case 2 
(A:3,B:0,C:2,D:3) 
S:6 28,80 17,80 11,90 8,80 8,8 10,1 8,7 
(A:0,B:0,C:1,D:1); 
S5 
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Figure 2. Morphometry in patients who underwent liver biopsy. Liver biopsies, divided according 
to Ishak score, showed significantly different percentages of fibrosis at morphometry among Ishak 
score≥ S3 and Ishak score <S3 (p ≤ 0.03). 
 
 
 19 
 
 
Figure 2.  Liver stiffness and ALT values at baseline and at different interval during treatment. 
Mean stiffness values at 3, 6, 9, and 12 months were not significantly different from those observed 
prior to therapy. Mean stiffness values at 18 and 24 months were statistically different from those 
observed prior to therapy. Mean ALT values during therapy were not significantly different from 
those observed before. Abbreviation: ALT, alanine aminotransferase.  
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Figure 3. Changes in liver fibrosis at baseline (panel A) and after two years of follow-up 
(panel B). 
 
